Tribune News Service
New Delhi, August 7
World’s leading vaccine maker Serum Institute of India on Friday said it would produce up to 100 million Covid-19 vaccine doses for India and low- and middle-income countries as early as 2021.
The institute in a statement said it would price each dose of the vaccine for USD 3 which roughly translates into Indian Rupees 225.
SII issued the statement after entering into what it called a new landmark collaboration between the SII, GAVI (Global Alliance for Vaccines) and Bill and Melinda Gates Foundation.
SII to get $150 mn from Gates Foundation
Under the arrangement the Bill and Melinda Gates Goundation via its strategic investment fund will provide at-risk funding of USD 150 million to GAVI which will be used to support the SII to manufacture the potential vaccine candidates.
“Vaccines will be priced at maximum USD 3 per dose and made available to the 92 countries included in GAVI’s COVAX Advance Market Commitment,” Adar Poonawala-led SII said in a statement.
Pune based Serum Institute has partnered with Oxford University and British Swedish Pharma firm Astra Zeneca to mass produce the frontrunner COVID 19 vaccine Covishield which has entered phase 3 clinical trials in some countries after showing safety and immune response in phase 1 and 2 studies in the UK.
Indian Drug controller has also permitted SII to undertake phase 2 and 3 human trials on Covishield in India.
Called pan-coronavirus vaccine, it was found effective in pr...
Asks Centre to share vaccine formula with other companies to...
On Monday, 48 bodies found near Ganga ghats in Buxar
On Friday, India recorded highest ever 4,14,188 cases
Active cases account for 16.16 per cent of total infections